The powerful combination of CDMO + API fully embodies the strategic principle of 1+1＞2, positioning the company to become one of the core strategic suppliers for domestic innovative pharmaceutical enterprises.
Since 2019, there has been a growing number of cooperation cases between innovative drug enterprises and API & CDMO suppliers for generic drugs.
On the one hand, when original innovative drug developers select outsourcing partners for API supply, leading CDMO companies such as Joincare Pharmaceutical, WuXi AppTec, and Apeloa Pharmaceutical are widely engaged via associated review and approval. This reflects the prominent advantages of top-tier CDMOs in innovative APIs and high-difficulty API development and production.
On the other hand, in the medium term, regarding process scale-up and cost management for the commercial production of innovative drugs, integrated API+CDMO enterprises with strong R&D and manufacturing capabilities possess inherent competitive advantages.
